Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Proof of concept study of RECCE327 topical antibiotic therapy for infected burn wounds in adults

Next Previous
Trial Profile

Proof of concept study of RECCE327 topical antibiotic therapy for infected burn wounds in adults

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RECCE 327 (Primary)
  • Indications Bacterial infections; Burn infections; Gram-negative infections; Gram-positive infections; Skin infections; Wound infections
  • Focus Proof of concept; Therapeutic Use
  • Acronyms RECCE327 PoC

Most Recent Events

  • 26 Feb 2024 According to a Recce Pharmaceuticals media release, An independent committee has awarded Recce the rights to move onto a phase I/II clinical trial. The company has given further safety approvals to expand. Patients will be treated with R327 either daily or every second day for 14 days. Those patients will be housed at the NSW-based Liverpool Hospital.
  • 13 Sep 2023 According to a Recce Pharmaceuticals media release, company has received a fund raise and this funds will be used for this study.
  • 23 Aug 2023 According to a Recce Pharmaceuticals media release, company has completed Stage 1 and is now progressing towards stage 2 part of the study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top